Navigation Links
Luminex Corporation Reports Third Quarter 2010 Results
Date:11/4/2010

tation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex' or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; demand for our MAGPIX system; integration of BSD Robotics; our relationship with Tecan Group; our investment in new products and our ability to maintain our edge in the marketplace, deliver high performa
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
2. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
3. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
4. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
6. Luminex Corporation to Present at UBS Global Life Sciences Conference
7. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
8. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
9. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
10. Gentris Corporation Names New Chief Scientific Advisor
11. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Amgen (NASDAQ: ... quarter of 2014. Key results include: , Total ... percent product sales growth driven by strong performance across ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... to $2.37, driven by higher revenues and a significant ...
(Date:7/29/2014)... Inc. (NASDAQ: SQNM ), a life sciences ... revenues of $39.8 million for the second quarter of ... $24.5 million for the second quarter of 2013. ... on May 30, 2014, has been accounted for as ... excluded from continuing operations for all periods. ...
(Date:7/29/2014)... July 29, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... public offering of 8,333,333 shares of its common  stock at ... of the common stock was offered by Pfenex. In addition, ... up to 1,250,000 additional shares of common stock at the ... traded on the NYSE MKT under the symbol "PFNX." ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 As the ... working with its partners to both purchase critical emergency supplies ... the US to Liberia. These supplies will contain materials used ... the most heavily populated areas of the country. , ... involved in the response to the Ebola outbreak in the ...
(Date:7/29/2014)... 29, 2014 The Board of Governors of ... Hart LLP ’s Connie Akridge to serve as ... as President of the Foundation. Akridge served as President of ... a partner at Holland & Hart in Las Vegas, providing ... matters to insurance and healthcare clients for more than 25 ...
(Date:7/29/2014)... 2014 CarePoint Health is proud ... our network, CarePoint Health Medical Group. Our system ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ... represents CarePoint Health’s commitment to provide the highest ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... behalf of individuals who allegedly suffered serious liver ... continue to move forward in a multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to an ... certain deadlines pertaining to bellwether case and ...
(Date:7/29/2014)... Denham Springs, LA (PRWEB) July 29, 2014 ... long holiday across the United States usually celebrated throughout ... More recently though, those summer days now mark the ... increase in crashes involving teen drivers. In 2012 ... drivers during the period from Memorial Day to Labor ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... Blue Shield of,Minnesota (Blue Cross) today released its financial ... of 0.3 percent ($25.1 million) on,full-year revenues of $8.4 ... offset $104 million in operating losses. Blue,Cross remains financially ... claims and operating expenses., More than 90 cents ...
... THURSDAY, April 17 (HealthDay News) -- The antidepressant Prozac ... their more plastic youthful condition in animal experiments, researchers ... new explanation for the antidepressant activity of the medication ... be used to treat other conditions caused by malfunction ...
... WASHINGTON, April 17 The Better Hearing,Institute (BHI) announced ... ( http://www.hearingcheck.org ), a nationwide campaign to,help millions of ... to,unaddressed hearing loss. The campaign will serve as the ... during the month of May., Spouses, Baby Boomers ...
... to improve ... patient access, HARRISBURG, Pa., April ... of Philadelphia as,its new president. Dr. Gamba, who served as president-elect for ... be a major focus of the organization., "All Pennsylvanians deserve access ...
... (Nasdaq: CTGX ),an international information technology (IT) solutions ... 2008 first quarter,financial results on April 23, 2008 after ... to discuss its financial results and business,strategy on Thursday, ... and Chief Executive Officer James R. Boldt will lead ...
Cached Medicine News:Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2007 Financial Results 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:Better Hearing Institute Kicks Off the Across America Hearing Check Challenge for Better Hearing and Speech Month, Bringing Better Quality of Life Back to Millions of Americans 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:CTG Announces 2008 First Quarter Conference Call and Webcast Information 2
... role within the orthopaedic industry, DePuy Orthopaedics ... industry's leading fixed-bearing implant, the P.F.C. SIGMA ... clinically proven technology of the LCS Knee ... ,The result is the P.F.C. SIGMA RP ...
The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i...
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
Medicine Products: